Auxilius Pharma Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • M&A
  • (Announced)

  • Latest Deal Amount
  • $29.5M

  • Investors
  • 6

Auxilius Pharma General Information

Description

Operator of a pharmaceutical company intended to focus on optimizing and further developing well-established medications. The company specializes in the formulation of generic oncological drugs in a convenient dosage form, enabling medical professionals to find therapies to treat cancer patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 86/410 Hoża Street
  • Warsaw
  • Poland
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 86/410 Hoża Street
  • Warsaw
  • Poland

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Auxilius Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 26-Aug-2026 $29.5M Announced Clinical Trials - Phase 1
5. Later Stage VC (Series D) 19-Nov-2025 Completed Clinical Trials - Phase 1
4. Later Stage VC 15-Jun-2023 Cancelled Clinical Trials - Phase 1
3. Seed Round 04-Oct-2022 Completed Clinical Trials - Phase 1
2. Seed Round 23-Dec-2021 $730K $1.4M Completed Clinical Trials - Phase 1
1. Seed Round 09-Mar-2021 $668K $668K Completed Clinical Trials - Phase 1
To view Auxilius Pharma’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Auxilius Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Auxilius Pharma Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
ff Venture Capital Venture Capital Minority
NCBR Investment Fund Venture Capital Minority
CofounderZone Venture Capital Minority
Forum TFI Corporation Minority
Angel (individual) Minority
You’re viewing 5 of 6 investors. Get the full list »

Auxilius Pharma FAQs

  • When was Auxilius Pharma founded?

    Auxilius Pharma was founded in 2018.

  • Where is Auxilius Pharma headquartered?

    Auxilius Pharma is headquartered in Warsaw, Poland.

  • What is the size of Auxilius Pharma?

    Auxilius Pharma has 6 total employees.

  • What industry is Auxilius Pharma in?

    Auxilius Pharma’s primary industry is Pharmaceuticals.

  • Is Auxilius Pharma a private or public company?

    Auxilius Pharma is a Private company.

  • What is the current valuation of Auxilius Pharma?

    The current valuation of Auxilius Pharma is .

  • What is Auxilius Pharma’s current revenue?

    The current revenue for Auxilius Pharma is .

  • How much funding has Auxilius Pharma raised over time?

    Auxilius Pharma has raised $6.43M.

  • Who are Auxilius Pharma’s investors?

    ff Venture Capital, NCBR Investment Fund, CofounderZone, Forum TFI, and are 5 of 6 investors who have invested in Auxilius Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process